Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ketoanalogues are **nitrogen-free structural analogues of essential amino acids**. They lack the amine group present in standard amino acids and instead have a corresponding keto group. In clinical practice, especially nephrology, they are used as **medical foods or supplements** designed primarily for patients with chronic kidney disease who require protein restriction but still need adequate nutrition. By providing these compounds alongside a low-protein diet, it is possible to reduce the intake of nitrogenous waste while allowing the body to synthesize needed proteins after transamination with available ammonia or other amines. Ketoanalogues themselves are not therapeutic targets such as receptors or enzymes; rather, they are small molecules used therapeutically. The term "ketoanalogue" refers broadly to this class and not a specific molecular target—thus it is **not considered a drug target** like an enzyme or receptor would be. Common products include mixtures such as Ketosteril®, which contains several different ketoacid analogues of essential amino acids along with some free L-amino acids. These preparations help manage complications associated with advanced kidney disease by reducing uremic toxins derived from protein metabolism while maintaining nutritional status[1]. Because "ketoanalogue" does not refer to any single molecule nor any biological macromolecule acting as a drug target (e.g., receptor/enzyme/transporter), listing it as a therapeutic target is incorrect. > Ketoanalogues are breakdown forms of amino acids... However, they do not include [the] part... that can be harder on kidneys—that part is nitrogen... They play many roles... beyond protein and muscles...[1] Ketoanalogues should not be listed among classical drug targets but rather classified under medical foods/supplements used adjunctively in certain diseases like CKD[1].
Serve as nitrogen-free precursors that can be transaminated into essential amino acids without increasing nitrogen load
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Keto-analogue.